Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.9K
3.9K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

14.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
14.1K
Types of RNA01:20

Types of RNA

16.5K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
16.5K
MicroRNAs01:22

MicroRNAs

4.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

24.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retroviral insertions contributed to the divergence of human and chimpanzee brains.

bioRxiv : the preprint server for biology·2025
Same author

Genomic Imprinting: Insights into Diverse Epigenetic Regulatory Mechanisms.

Cytogenetic and genome research·2025
Same author

Beyond the Transcript: Translating Non-Coding RNAs and Their Impact on Cellular Regulation.

Cancers·2025
Same author

IER3: exploring its dual function as an oncogene and tumor suppressor.

Cancer gene therapy·2025
Same author

<i>PITAR</i>, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing <i>TRIM28</i> mRNA.

eLife·2024
Same author

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.

British journal of cancer·2024
Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026
Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026
Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026
Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026
Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026
Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026
See all related articles

Related Experiment Video

Updated: Apr 9, 2026

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.5K

Long noncoding RNAs and neuroblastoma.

Gaurav Kumar Pandey1, Chandrasekhar Kanduri1

  • 1Department of Medical Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Oncotarget
|June 19, 2015
PubMed
Summary
This summary is machine-generated.

Long noncoding RNAs (lncRNAs) are emerging as key players in neuroblastoma, a childhood cancer. Understanding their roles could improve prognosis and treatment for high-risk neuroblastoma patients.

Keywords:
MYCNNBAT1neuroblastomaneuronal differentiationnoncoding RNA

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Apr 9, 2026

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neuroblastoma affects infants, with poor survival rates for high-risk patients despite aggressive treatment.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in various cancers.
  • The specific functions of lncRNAs in neuroblastoma are still under investigation.

Purpose of the Study:

  • To review the current understanding of lncRNAs in neuroblastoma.
  • To discuss the mechanistic roles of lncRNAs in neuroblastoma development.
  • To explore the link between lncRNA expression and neuroblastoma cell differentiation.

Main Methods:

  • Literature review of studies on lncRNAs and neuroblastoma.
  • Analysis of known mechanistic roles of lncRNAs in cancer pathogenesis.
  • Examination of the relationship between lncRNA expression and neuroblastoma cell differentiation capacity.

Main Results:

  • lncRNAs play significant roles in neuroblastoma pathogenesis.
  • Specific lncRNAs are associated with the differentiation capacity of neuroblastoma cells.
  • lncRNAs mapping to the 6p22 hotspot show potential as biomarkers.

Conclusions:

  • lncRNAs offer a novel perspective on neuroblastoma prognosis and treatment.
  • Further research into lncRNAs could lead to improved therapeutic strategies for high-risk neuroblastoma.
  • lncRNAs may serve as valuable biomarkers for neuroblastoma patient outcomes.